Novavax Swine Flu (NASDAQ: NVAX)

novavax-roller-coasterSince it started trading, Novavax stock has been a roller coaster if you compare it with all the swine flu stocks. The 500% plus increase of Novavax share price since the swine flu symptoms invaded the media, puts this company at the peak of the high-yielding list of stocks to watch, but also, at the highest risk.

Novavax’s strategy involves isolating three proteins from the virus that flag the human immune system, which then churns out neutralizing antibodies against the proteins from the influenza virus.

Novavax antibodies are robust enough to fight off the actual flu virus if an immunized person becomes infected with the influenza virus.

novavax-whiteThe VLP vaccine may also prove easier to develop since all it requires is an accurate genetic sequence of three critical virus genes.

Novavax flu vaccines showed good results in tests against seasonal and bird flu and company stands ready to try its strategy against the swine flu.

Novavax NVAX Company Overview

Novavax Inc. is a clinical stage biotech company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology.

novavax-imagesUtilizing a new and efficient manufacturing approach these VLP technologies are able to provide cures for various circulating viruses.

Novavax Pharmaceuticals have a vision centred on a holistic approach to controlling the spread of disease like the swine flu or bird flue, and a long-term goal of being able to rapidly deliver a customized H1N1 vaccine in the midst of a pandemic crisis.